Free Trial
→ My public warning after 55 years of watching the markets (From Weiss Ratings) (Ad)tc pixel
OTCMKTS:HYPMY

Hypermarcas Q2 2026 Earnings Results & Report

Hypermarcas logo
$5.30 0.00 (0.00%)
As of 10/9/2026 09:45 AM Eastern

Hypermarcas beat analyst earnings expectations in its Q2 2026 results, released August 6, 2026. The company reported EPS of $0.14 versus the $0.13 consensus estimate.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
After Market Closes

Hypermarcas EPS Results

Actual EPS
$0.14
Consensus EPS
$0.13
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Hypermarcas Revenue Results

Actual Revenue
N/A
Expected Revenue
$452.49 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Hypermarcas' next earnings date is estimated for Wednesday, November 11, 2026, based on past reporting schedules.

Conference Call Resources

Hypermarcas Q2 2026 Earnings FAQ

Hypermarcas (OTCMKTS:HYPMY) reported earnings of $0.14 per share for Q2 2026, beating the consensus estimate of $0.13. The report was announced on Thursday, August 6, 2026.

Hypermarcas' next earnings date is estimated for Wednesday, November 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for Hypermarcas on the company's earnings history page.

Hypermarcas Earnings Headlines

Hypermarcas (OTCMKTS:HYPMY) Sees Unusually-High Trading Volume - Should You Buy?
October 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31092953
Hypermarcas (OTCMKTS:HYPMY) Reaches New 12-Month High - Should You Buy?
October 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31087455
America’s AI Doomsday Scenario
China controls 90% of the production of two critical minerals essential to AI data centers, semiconductors, and quantum computing. In 2024, AI data centers consumed as much energy as New York and Chicago combined, underscoring the urgency of securing domestic supply. Jamie Dimon and Condoleezza Rice are now backing Project Phoenix, a major push to rebuild America's mineral supply chain.tc pixel
October 12 at 1:00 AM  |  Weiss Ratings (Ad)
Head to Head Comparison: NRx Pharmaceuticals (NASDAQ:NRXP) & Hypermarcas (OTCMKTS:HYPMY)
October 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31086043
Hypera ON ADR (HYPMY)
September 27, 2026  |  es.investing.comhttps://es.investing.com/equities/hypermarcas-sa-news
Hypera S.A. (HYPMY) Q2 2026 Earnings Call Transcript
August 11, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4934927-hypera-s-a-hypmy-q2-2026-earnings-call-transcript
See More Hypermarcas Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Hypermarcas? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Hypermarcas and other key companies, straight to your email.

About Hypermarcas

Hypermarcas (OTCMKTS:HYPMY) S.A. was a Brazilian consumer healthcare company that developed, manufactured and marketed pharmaceutical and healthcare products. Its portfolio included over-the-counter medicines, prescription products, vitamins and other consumer health brands sold through pharmacies and retail channels.

The company was historically associated with well-known Brazilian brands such as Benegrip, Biotônico Fontoura, Doril, Engov and Epocler. Hypermarcas also previously operated in personal care, beauty, household cleaning and other consumer categories, but divested many of those businesses as it concentrated on pharmaceuticals and healthcare.

In 2018, Hypermarcas changed its corporate name to Hypera S.A., adopting the Hypera Pharma identity. The company’s principal market has been Brazil, with its operations focused on serving the Brazilian healthcare and pharmaceutical market.

View Hypermarcas Profile
Earnings Tools